KarunaNews Story

Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate. The study will evaluate the vaccine for safety, tolerability, and the level of immune response, as both a primary series and a booster dose in up to 1,420 healthy adults from 18 to 55 years-old.